Evaluation of patients with adrenal incidentalomas

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 20, Issue 3, 2013, Pages 161-169

  Kannan, Subramanian ^a   Remer, Erick M ^a   Hamrahian, Amir H ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Adrenal adenoma; Adrenal incidentaloma; CT scan; Pheochromocytoma; Primary aldosteronism; Subclinical Cushing's syndrome

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; CORTICOSTERONE; CORTICOTROPIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; HYDROCORTISONE; METADRENALIN; NORMETADRENALIN; PRASTERONE SULFATE; SPIRONOLACTONE; TESTOSTERONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL INCIDENTALOMA; ADRENAL TUMOR; ALDOSTERONE BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CORTICOTROPIN BLOOD LEVEL; CUSHING SYNDROME; FINE NEEDLE ASPIRATION BIOPSY; FOLLOW UP; HORMONE RELEASE; HUMAN; HYDROCORTISONE RELEASE; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOKALEMIA; MUSCLE WEAKNESS; PHEOCHROMOCYTOMA; PRIMARY HYPERALDOSTERONISM; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; VIRILIZATION;

ADRENAL GLAND NEOPLASMS; DECISION TREES; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASM STAGING;

EID: 84879225990     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e328360a43b     Document Type: Review

References (87)

1. Cawood TJ, Hunt PJ, O'Shea D, et al. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol 2009; 161:513-527.
2. Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 2007; 356:601-610. (Pubitemid 46220820)
3. Kloos RT, GrossMD, Francis IR, et al. Incidentally discovered adrenal masses. Endocr Rev 1995; 16:460-484.
4. Mansmann G, Lau J, Balk E, et al. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 2004; 25:309-340. (Pubitemid 38528713)
5. Barzon L, Sonino N, Fallo F, et al. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 2003; 149:273-285. (Pubitemid 37304697)
6. Bovio S, Cataldi A, Reimondo G, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest 2006; 29:298-302. (Pubitemid 43905318)
7. Young WF Jr. Management approaches to adrenal incidentalomas. A view from Rochester, Minnesota. Endocrinol Metab Clin North Am 2000; 29:159-185; x.
8. Kasperlik-Zaluska AA, Otto M, Cichocki A, et al. Incidentally discovered adrenal tumors: a lesson from observation of 1444 patients. Horm Metab Res 2008; 40:338-341. (Pubitemid 351859445)
9. Aron DC. Incidentalomas. Preface. Best Pract Res Clin Endocrinol Metab 2012; 26:1-2.
10. Taskin HE, Berber E. Retroperitoneal tumors that may be confused as adrenal pathologies. J Surg Oncol 2012; 106:600-603.
11. Zeiger MA, Siegelman SS, Hamrahian AH. Medical and surgical evaluation and treatment of adrenal incidentalomas. J Clin Endocrinol Metab 2011; 96:2004-2015.
12. Hamrahian AH, Ioachimescu AG, Remer EM, et al. Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab 2005; 90:871-877. (Pubitemid 40279211)
13. Korobkin M, Brodeur FJ, Yutzy GG, et al. Differentiation of adrenal adenomas from nonadenomas using CT attenuation values. AJR Am J Roentgenol 1996; 166:531-536. (Pubitemid 26065155)
14. Mayo-Smith WW, Boland GW, Noto RB, Lee MJ. State-of-the-art adrenal imaging. Radiographics 2001; 21:995-1012.
15. Caoili EM, Korobkin M, Francis IR, et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology 2002; 222:629-633. (Pubitemid 34215205)
16. Korobkin M, Brodeur FJ, Francis IR, et al. Delayed enhanced CT for differentiation of benign from malignant adrenal masses. Radiology 1996; 200:737-742. (Pubitemid 26282273)
17. Korobkin M, Brodeur FJ, Francis IR, et al. CT time-attenuation washout curves of adrenal adenomas and nonadenomas. AJR Am J Roentgenol 1998; 170:747-752. (Pubitemid 28106677)
18. Sangwaiya MJ, Boland GW, Cronin CG, et al. Incidental adrenal lesions: accuracy of characterization with contrast-enhanced washout multidetector CT - 10-min delayed imaging protocol revisited in a large patient cohort. Radiology 2010; 256:504-510.
19. Kamiyama T, Fukukura Y, Yoneyama T, et al. Distinguishing adrenal adenomas fromnonadenomas: combined use of diagnostic parameters of unenhanced and short 5-min dynamic enhanced CT protocol. Radiology 2009; 250:474-481.
20. Foti G, Faccioli N, Mantovani W, et al. Incidental adrenal lesions: accuracy of quadriphasic contrast enhanced computed tomography in distinguishing adenomas from nonadenomas. Eur J Radiol 2012; 81:1742-1750.
21. Yoon JK, Remer EM, Herts BR. Incidental pheochromocytoma mimicking adrenal adenoma because of rapid contrast enhancement loss. AJR Am J Roentgenol 2006; 187:1309-1311. (Pubitemid 44630837)
22. Park BK, Kim CK, Kwon GY, Kim JH. Re-evaluation of pheochromocytomas on delayed contrast-enhanced CT: washout enhancement and other imaging features. Eur Radiol 2007; 17:2804-2809. (Pubitemid 47603975)
23. Lee MJ, Hahn PF, Papanicolaou N, et al. Benign and malignant adrenal masses: CT distinction with attenuation coefficients, size, and observer analysis. Radiology 1991; 179:415-418.
24. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000; 85:637-644.
25. Zeiger MA, Thompson GB, Duh QY, et al. The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocr Pract 2009; 15 (Suppl. 1):1-20.
26. Sturgeon C, Shen WT, Clark OH, et al. Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? J Am Coll Surg 2006; 202:423-430. (Pubitemid 43356216)
27. Pantalone KM, Gopan T, Remer EM, et al. Change in adrenal mass size as a predictor of a malignant tumor. Endocr Pract 2010; 16:577-587.
28. Yener S, Ertilav S, Secil M, et al. Prospective evaluation of tumor size and hormonal status in adrenal incidentalomas. J Endocrinol Invest 2010; 33:32- 36.
29. Israel GM, Korobkin M, Wang C, et al. Comparison of unenhanced CT and chemical shift MRI in evaluating lipid-rich adrenal adenomas. AJR Am J Roentgenol 2004; 183:215-219. (Pubitemid 38789040)
30. Outwater EK, Siegelman ES, Radecki PD, et al. Distinction between benign and malignant adrenal masses: value of T1-weighted chemical-shift MR imaging. AJR Am J Roentgenol 1995; 165:579-583.
31. Haider MA, Ghai S, Jhaveri K, Lockwood G. Chemical shift MR imaging of hyperattenuating (>10 HU) adrenal masses: does it still have a role? Radiology 2004; 231:711-716. (Pubitemid 38668087)
32. McDermott S, O'Connor OJ, Cronin CG, Blake MA. Radiological evaluation of adrenal incidentalomas: current methods and future prospects. Best Pract Res Clin Endocrinol Metab 2012; 26:21-33.
33. Bae KT, Fuangtharnthip P, Prasad SR, et al. Adrenal masses: CT characterization with histogram analysis method. Radiology 2003; 228:735- 742. (Pubitemid 37025484)
34. Remer EM, Motta-Ramirez GA, Shepardson LB, et al. CT histogram analysis in pathologically proven adrenal masses. AJR Am J Roentgenol 2006; 187:191-196. (Pubitemid 46100168)
35. Halefoglu AM, Bas N, Yasar A, Basak M. Differentiation of adrenal adenomas from nonadenomas using CT histogram analysis method: a prospective study. Eur J Radiol 2010; 73:643-651.
36. Jhaveri KS, Wong F, Ghai S, Haider MA. Comparison of CT histogram analysis and chemical shift MRI in the characterization of indeterminate adrenal nodules. AJR Am J Roentgenol 2006; 187:1303-1308. (Pubitemid 44630836)
37. Ho LM, Paulson EK, Brady MJ, et al. Lipid-poor adenomas on unenhanced CT: does histogram analysis increase sensitivity compared with a mean attenuation threshold? AJR Am J Roentgenol 2008; 191:234- 238. (Pubitemid 351955200)
38. Meyer-Rochow GY, Schembri GP, Benn DE, et al. The utility of metaiodobenzylguanidine single photon emission computed tomography/computed tomography (MIBG SPECT/CT) for the diagnosis of pheochromocytoma. Ann Surg Oncol 2010; 17:392-400.
39. Vanderveen KA, Thompson SM, Callstrom MR, et al. Biopsy of pheochromocytomas and paragangliomas: potential for disaster. Surgery 2009; 146:1158-1166.
40. Erozen YS. Fine needle aspiration cytology. In: Sidawy MK, Ali SZ, et al., editors. Kidney and adrenal gland, 1st ed Philadelphia, PA: Churchill Livingstone Elsevier; 2007. pp. 299-344.
41. Lack EE, Wieneke JA. Adrenal glands. In: Bostwick DG, Cheng L, et al., editors. Urologic surgical pathology, 2nd ed Mosby Elsevier; 2008. pp. 952- 1008.
42. Terzolo M, Bovio S, Pia A, et al. Management of adrenal incidentaloma. Best Pract Res Clin Endocrinol Metab 2009; 23:233-243.
43. Arnaldi G, Masini AM, Giacchetti G, et al. Adrenal incidentaloma. Braz J Med Biol Res 2000; 33:1177-1189.
44. Graham DJ, McHenry CR. The adrenal incidentaloma: guidelines for evaluation and recommendations for management. Surg Oncol Clin N Am 1998; 7:749-764. (Pubitemid 28436538)
45. Erbil Y, Ademoglu E, Ozbey N, et al. Evaluation of the cardiovascular risk in patients with subclinical Cushing syndrome before and after surgery. World J Surg 2006; 30:1665-1671. (Pubitemid 44411221)
46. Tauchmanova L, Rossi R, Biondi B, et al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab 2002; 87:4872-4878. (Pubitemid 35316318)
47. Rossi R, Tauchmanova L, Luciano A, et al. Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab 2000; 85:1440-1448. (Pubitemid 32289484)
48. Oki K, Yamane K, Nakanishi S, et al. Influence of adrenal subclinical hypercortisolism on hypertension in patients with adrenal incidentaloma. Exp Clin Endocrinol Diabetes 2012; 120:244-247.
49. Chiodini I, Morelli V, Salcuni AS, et al. Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab 2010; 95:2736-2745.
50. Toniato A, Merante-Boschin I, Opocher G, et al. Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann Surg 2009; 249:388-391.
51. Di Dalmazi G, Vicennati V, Rinaldi E, et al. Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study. Eur J Endocrinol 2012; 166:669-677.
52. Chiodini I, Morelli V, Masserini B, et al. Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian multicenter study. J Clin Endocrinol Metab 2009; 94:3207-3214.
53. Tauchmanova L, Guerra E, Pivonello R, et al. Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome. J Endocrinol Invest 2009; 32:390-394.
54. Morelli V, Eller-Vainicher C, Salcuni AS, et al. Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: a multicenter longitudinal study. J Bone Miner Res 2011; 26:1816- 1821.
55. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93:1526-1540. (Pubitemid 351656485)
56. Tateishi Y, Kouyama R, Mihara M, et al. Evaluation of salivary cortisol measurements for the diagnosis of subclinical Cushing's syndrome. Endocr J 2012; 59:283-289.
57. Reimondo G, Allasino B, Bovio S, et al. Pros and cons of dexamethasone suppression test for screening of subclinical Cushing's syndrome in patients with adrenal incidentalomas. J Endocrinol Invest 2011; 34:e1-e5.
58. Terzolo M, Reimondo G, Chiodini I, et al. Screening of Cushing's syndrome in outpatients with type 2 diabetes: results of a prospective multicentric study in Italy. J Clin Endocrinol Metab 2012; 97:3467-3475.
59. Bulow B, Jansson S, Juhlin C, et al. Adrenal incidentaloma - follow-up results from a Swedish prospective study. Eur J Endocrinol 2006; 154:419-423.
60. Motta-Ramirez GA, Remer EM, Herts BR, et al. Comparison of CT findings in symptomatic and incidentally discovered pheochromocytomas. AJR Am J Roentgenol 2005; 185:684-688.
61. Grumbach MM, Biller BM, Braunstein GD, et al. Management of the clinically inapparent adrenal mass ('incidentaloma'). Ann Intern Med 2003; 138:424- 429. (Pubitemid 36262654)
62. Stenstrom G, Svardsudd K. Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry Data. Acta Med Scand 1986; 220:225-232. (Pubitemid 17168529)
63. Mannelli M, Lenders JW, Pacak K, et al. Subclinical phaeochromocytoma. Best Pract Res Clin Endocrinol Metab 2012; 26:507-515.
64. Sane T, Schalin-Jantti C, Raade M. Is biochemical screening for pheochromocytoma in adrenal incidentalomas expressing low unenhanced attenuation on computed tomography necessary? J Clin Endocrinol Metab 2012; 97:2077-2083.
65. Rha SE, Byun JY, Jung SE, et al. Neurogenic tumors in the abdomen: tumor types and imaging characteristics. Radiographics 2003; 23:29-43. (Pubitemid 37421433)
66. Francis IR, Korobkin M. Pheochromocytoma. Radiol Clin North Am 1996; 34:1101-1112. (Pubitemid 26371249)
67. Jacques AE, Sahdev A, Sandrasagara M, et al. Adrenal phaeochromocytoma: correlation of MRI appearances with histology and function. Eur Radiol 2008; 18:2885-2892.
68. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002; 287:1427-1434. (Pubitemid 34250506)
69. Sawka AM, Jaeschke R, Singh RJ, Young WF Jr. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-h urinary metanephrines and catecholamines. J Clin Endocrinol Metab 2003; 88:553-558. (Pubitemid 36207789)
70. Pacak K, Eisenhofer G, Ahlman H, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab 2007; 3:92-102. (Pubitemid 46146962)
71. Neary NM, King KS, Pacak K. Drugs and pheochromocytoma - don't be fooled by every elevated metanephrine. N Engl J Med 2011; 364:2268- 2270.
72. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:3266-3281.
73. Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol 2006; 48:2293-2300. (Pubitemid 44873058)
74. McKenzie TJ, Lillegard JB, Young WF Jr, Thompson GB. Aldosteronomas - state of the art. Surg Clin North Am 2009; 89:1241-1253.
75. Terzolo M, Stigliano A, Chiodini I, et al. AME position statement on adrenal incidentaloma. Eur J Endocrinol 2011; 164:851-870.
76. Kim HY, Kim SG, Lee KW, et al. Clinical study of adrenal incidentaloma in Korea. Korean J Intern Med 2005; 20:303-309.
77. Hiramatsu K, Yamada T, Yukimura Y, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 1981; 141:1589-1593. (Pubitemid 12234064)
78. Mosso L, Carvajal C, Gonzalez A, et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42:161-165. (Pubitemid 36944590)
79. Stowasser M, Ahmed AH, Pimenta E, et al. Factors affecting the aldosterone/ renin ratio. Horm Metab Res 2012; 44:170-176.
80. Stowasser M, Gordon RD. Primary aldosteronism - careful investigation is essential and rewarding. Mol Cell Endocrinol 2004; 217:33-39. (Pubitemid 38596626)
81. Padwal RS, Hemmelgarn BR, Khan NA, et al. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension. Part 1. Blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2009; 25:279-286.
82. Kupers EM, Amar L, Raynaud A, et al. A clinical prediction score to diagnose unilateral primary aldosteronism. J Clin Endocrinol Metab 2012; 97:3530- 3537.
83. Mulatero P, di Cella SM, Monticone S, et al. 18-Hydroxycorticosterone, 18- hydroxycortisol, and 18-oxocortisol in the diagnosis of primary aldosteronism and its subtypes. J Clin Endocrinol Metab 2012; 97:881-889.
84. Ganeshan D, Bhosale P, Kundra V. Current update on cytogenetics, taxonomy, diagnosis, and management of adrenocortical carcinoma: what radiologists should know. AJR Am J Roentgenol 2012; 199:1283-1293.
85. Kievit J, Haak HR. Diagnosis and treatment of adrenal incidentaloma. A costeffectiveness analysis. Endocrinol Metab Clin North Am 2000; 29:69-90; viii-ix.
86. Bernini GP, Moretti A, Oriandini C, et al. Long-term morphological and hormonal follow-up in a single unit on 115 patients with adrenal incidentalomas. Br J Cancer 2005; 92:1104-1109. (Pubitemid 40546676)
87. Vassilatou E, Vryonidou A, Michalopoulou S, et al. Hormonal activity of adrenal incidentalomas: results from a long-term follow-up study. Clin Endocrinol (Oxf) 2009; 70:674-679.